Shukra Pharmaceuticals Profit & Loss Annual

BSE: 524632 | NSE: SHUKRAPHAR | ISIN: INE551C01044 | Sector: Biotechnology & Drugs

53.59 +0.52 (0.98%)Updated : 08 Sep 2026

Research on

Interim Data

Annual Data

Fiscal Period	2026	2025	2024	2023
Period End Date	Mar 26	Mar 25	Mar 24	Mar 23
Total Operating Expense	31.43	22.86	57.22	55.31
Other Net	4.58	2.65	2.81	1.17
Total Adjustmentsto Net Income	0.00	0.00	-	0.00
Diluted Weighted Average Shares	44.12	43.79	437.88	67.24
Depreciation/ Amortization	3.44	3.00	2.05	1.84
Operating Income	25.30	9.72	17.35	3.53
Net Income	22.06	9.58	18.54	4.41
Income Availableto Com Excl Extra Ord	22.06	9.58	18.54	4.41
Other Operating Expenses Total	5.10	0.25	5.04	3.26
Net Income Before Taxes	28.79	13.34	19.88	4.44
Net Income After Taxes	22.06	9.58	18.54	4.41
Income Availableto Com Incl Extra Ord	22.06	9.58	18.54	4.41
Costof Revenue Total	15.85	8.11	44.49	45.32
Gross Profit	40.88	24.48	30.09	13.52
Interest Inc( Exp) Net- Non- Op Total	-1.09	0.96	-0.28	-0.26
Diluted Net Income	22.06	9.58	18.54	4.41
DPS- Common Stock Primary Issue	0.01	0.01	0.01	0.00
Provisionfor Income Taxes	6.73	3.76	1.35	0.04
period Type	-	-	-	-
Net Income Before Extra Items	22.06	9.58	18.54	4.41
Total Revenue	56.73	32.59	74.57	58.83
period Length	12.00	12.00	12.00	12.00
Revenue	56.73	32.59	74.57	58.83
Selling/ General/ Admin Expenses Total	7.04	11.50	5.65	4.89
Diluted Normalized EPS	0.50	0.22	0.04	0.07
Diluted EPS Excluding Extra Ord Items	0.50	0.22	0.04	0.07